A Study to Determine the Safety, Tolerability and Pharmacokinetics of PMZ-2010 (Centhaquin) in Healthy Volunteers
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Shock is a condition of reduced tissue perfusion, resulting in the inadequate delivery of
oxygen and nutrients that are necessary for cellular function. The current resuscitative
agents can extend patient's life to a limited extent. Centhaquin (PMZ-2010) in very low doses
reduced blood lactate levels, improved blood pressure, cardiac output, survival and proved to
be a highly effective resuscitative agent. The investigators are conducting a phase I
clinical study in humans to evaluate the safety, tolerability, pharmacokinetics and
pharmacodynamics of centhaquin citrate in normal healthy volunteers.